MedTrace Logo

Risperidone Augmentation for Treatment-Resistant Aggression in ADHD

NCT00297739 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2006-03-16

No results posted yet for this study

Summary

Primary objectives:

1. To assess the short-term efficacy of risperidone augmentation for treatment-resistant aggression in children with ADHD.
2. To assess the short-term safety and tolerability of risperidone augmentation in the same group of subjects.

Conditions

  • Aggression

Interventions

DRUG

Risperidone

Sponsors & Collaborators

  • Janssen, LP

    collaborator INDUSTRY

  • Armenteros, Jorge L., M.D., P.A.

    lead INDIV

Principal Investigators

  • Jorge L Armenteros, MD · Jorge L. Armenteros, M.D., P.A.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
7 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Completion
2005-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00297739 on ClinicalTrials.gov